New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

A new study shows that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

Scientists at St. Jude Children’s Research Hospital and University Health Network showed that the stage of B-cell development ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

It affects the B cell lymphocytes. Around 75 out of every 100 people with ALL (around 75%) are this type. B cell ALL can be further divided into subgroups, the most common subgroup is precursor B cell ...

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL — 3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone.

The FELIX study assessed efficacy of obe-cel among 127 adults (median age, 47 years; range, 20-81; 51.9% male) with relapsed or refractory B-cell ALL. Study participants had received a median two ...

Of the patients, 22.8% had extramedullary disease, and 28.3% had Philadelphia chromosome-positive B-cell ALL. Bridging therapy was administered to 92.9% of patients. Disclosures ...

Did non-relapse mortality rates vary by CAR T cell therapy product and how may this inform treatment choice? Yes. Among patients with large B cell lymphoma, we found a higher NRM rate of 7.4% in ...